SOURCE-LINKED STUDY SUMMARY
The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial.
Full paper summarizedQuality not appraised
- What was studied
- This phase 2 trial tested enobosarm’s effects on DXA lean mass, physical function, metabolic measures, and safety.
- Who / model studied
- The study randomized 120 healthy older adults: men over 60 and postmenopausal women, rather than patients with muscle-wasting disease.
- Studied dose & schedule
- Participants took oral enobosarm 0.1, 0.3, 1, or 3 mg, or placebo, daily for 86 days.
- What the study found
- At 3 mg, enobosarm improved total lean body mass and physical function versus placebo. Adverse-event incidence was similar across treatment groups.
- Limitations & context
- This short healthy-volunteer trial measured DXA lean mass rather than direct muscle hypertrophy, and its analysis population required study completion.
Read summary source ↗ · Prepared 10/6/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: full paper. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1007/s13539-011-0034-6